162 related articles for article (PubMed ID: 27789848)
21. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
23. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
24. Dolutegravir: successful experience in a challenging patient.
Bonadies G; Maraolo AE; Tambaro O; Palmiero G; Di Filippo G; Orlando R
AIDS; 2015 Jun; 29(10):1269-71. PubMed ID: 26035327
[No Abstract] [Full Text] [Related]
25. Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir.
Kandil MM; Badowski ME; Schriever CA
Int J STD AIDS; 2018 Jul; 29(8):831-833. PubMed ID: 29350111
[TBL] [Abstract][Full Text] [Related]
26. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
31. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
[TBL] [Abstract][Full Text] [Related]
32. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
33. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
34. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
35. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
Borghetti A; Baldin G; Ciccullo A; Gagliardini R; D'Avino A; Mondi A; Ciccarelli N; Lamonica S; Fanti I; Trecarichi E; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2016 Aug; 71(8):2359-61. PubMed ID: 27147306
[No Abstract] [Full Text] [Related]
36. Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.
Del Puente F; Pontali E; Torresin A; Cassola G
AIDS; 2019 Dec; 33(15):2446-2447. PubMed ID: 31764113
[No Abstract] [Full Text] [Related]
37. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
38. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
39. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
[TBL] [Abstract][Full Text] [Related]
40. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Auclair M; Guénantin AC; Fellahi S; Garcia M; Capeau J
PLoS One; 2020; 15(1):e0226924. PubMed ID: 31971958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
